#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Full analysis

Cardiologist and lipidologist Michael Davidson, CEO of NewAmsterdam Pharma, makes the case for treating LDL cholesterol the same way we treat high blood pressure — as a causal driver of disease to be addressed early in life, not after a heart attack. He then explains the history and science behind obicetrapib, a new oral LDL-lowering drug that may also reduce Alzheimer's risk, particularly in people who carry the APOE4 gene.

What was covered

• The "8 gram rule" for lifetime LDL exposure. Davidson argued that heart disease risk accumulates from a lifetime cholesterol burden — 200 mg/dL for 40 years equals the same 8 grams as 80 mg/dL for 100 years. His point: start lowering LDL earlier rather than waiting for a cardiac event, because once heart failure is established, LDL lowering no longer helps.

• Why high HDL ("good cholesterol") is not a free pass. A landmark genetic analysis confirmed that no purely HDL-raising gene is independently associated with cardiovascular protection — the benefit always involved simultaneous LDL or triglyceride lowering. Davidson said physicians who reassure patients because their HDL is high are acting on obsolete information.

• The long history of CETP inhibitor failures. Four earlier drugs in this class failed or were abandoned: Pfizer's torcetrapib caused dangerous aldosterone surges and killed patients; Roche's dalcetrapib raised HDL but moved MACE (major adverse cardiac events — heart attacks, strokes, cardiovascular deaths) not at all; Lilly's evacetrapib showed a total mortality benefit but was stopped at two years for futility before the drug curves could separate; Merck's anacetrapib proved LDL lowering with CETP inhibition does reduce events but was abandoned because it accumulated in fat tissue and couldn't be cleared for years.

• Obicetrapib's current clinical profile. At 10 mg daily, the drug lowers LDL-C roughly 45–50% as monotherapy, up to 55% combined with ezetimibe, cuts Lp(a) (a separate inherited cardiac risk marker) by roughly 50%, reduces small LDL particles by 90%, and — unlike statins — appears to lower rather than raise diabetes risk. Three major phase 3 trials (BROOKLYN in familial hypercholesterolemia, BROADWAY and ROSE in ASCVD patients) are complete; the drug is filed for approval in Europe and does not require an outcomes trial there. The PREVAIL outcomes trial (9,500 patients, global) is in year three and is expected to hit its minimum follow-up milestone by end of 2025.

• The APOE4–Alzheimer's connection and obicetrapib's potential role. Roughly 25% of people carry one copy of APOE4 (about 3× increased Alzheimer's risk); roughly 2–3% carry two copies (about 10× risk). Davidson explained that brain cholesterol metabolism is entirely separate from the rest of the body — there is no LDL in the brain, only HDL-like particles carrying APOE — and that APOE4 impairs cholesterol clearance from neurons, setting off the amyloid-tau cascade. HDL from the bloodstream does cross the blood-brain barrier and appears to help clear this toxic buildup. In a pre-specified analysis of 2,500 Broadway patients, obicetrapib reduced the Alzheimer's biomarker P-tau 217 overall; in the roughly 30 APOE4 homozygous patients, every measured biomarker (P-tau 181, amyloid 40/42 ratio, GFAP, neurofilament light) improved by statistically significant margins.

• Fish oil, DHA, and brain delivery. Davidson distinguished EPA (primarily antithrombotic/anti-inflammatory, cardiovascular benefit supported by the REDUCE-IT trial) from DHA (the dominant fat in the brain). The problem: standard fish oil DHA does not cross the blood-brain barrier efficiently. A recently identified transporter (MFSD2A) requires DHA in the "lyso-PC" (lysophosphatidylcholine) form to get into the brain. A supplement in that form — currently available in krill-oil-based products; a fish-oil-based version is coming — is under investigation through Davidson's separate venture, Jocasta.

• Klotho as a potential Alzheimer's therapy. Davidson briefly described an early-stage program to bring the protein klotho — associated with cognitive protection and longevity — into human clinical trials, with IND filing and first-in-human data hoped for within roughly a year. Mechanism of action remains unknown.

Notable claims & predictions

• Davidson: "If you keep your LDL below 80 throughout your lifetime, you don't get heart disease." He frames this as the implication of cumulative exposure data.

• Davidson: A 1 mmol/L (approximately 38.8 mg/dL) absolute reduction in LDL reliably produces a 22% relative reduction in cardiovascular events — linear, and independent of how the LDL is lowered (drug, genetics, or otherwise).

• Davidson on APOE4 homozygotes: Genetic loss-of-function variants in CETP "basically took the E4 risk away" in one cohort study — carriers had Alzheimer's risk comparable to non-APOE4 individuals. He called that a "profound benefit."

• Davidson: Statins raise LDL particle (Lp[a]) levels and do not lower small dense LDL particles well; obicetrapib does the opposite on both counts, making it "a great companion drug to statins."

• Davidson on P-tau 217: He believes this blood biomarker — which tracks amyloid burden in the brain and predicts progression from normal cognition to MCI — may become a regulatory endpoint for Alzheimer's prevention trials, analogous to LDL in cardiovascular disease. Regulators currently require demonstrated cognitive improvement, not just biomarker change.

• Davidson on DHA: Standard fish-oil supplementation almost certainly does not increase DHA in the brain to a meaningful degree; only the lyso-PC form of DHA can cross the blood-brain barrier via the MFSD2A transporter.

Fact check

Claim (Davidson): "Torcetrapib was stopped due to increased mortality, both cardiovascular and non-cardiovascular." Accurate. The ILLUMINATE trial was halted in December 2006 after excess deaths in the torcetrapib arm; the cause was later attributed to off-target aldosterone stimulation (confirmed by blood pressure rises in rats, which have no endogenous CETP), not CETP inhibition itself. Well established.

Claim (Davidson): The Merck anacetrapib trial (REVEAL) enrolled 30,000 patients, ran four years, started at baseline LDL of 60 mg/dL, achieved 17% LDL lowering (11 mg/dL absolute), and showed 9% relative risk reduction. These figures are consistent with published REVEAL data; the trial is well documented in the literature.

Claim (Davidson): "For a 1 millimole [38.8 mg/dL] of LDL, you get a 22% relative risk reduction." This figure is widely cited and derives from the Cholesterol Treatment Trialists' meta-analyses. It is a reasonable summary of the literature, though the effect is somewhat larger in high-risk secondary-prevention populations and somewhat smaller in lower-risk primary-prevention settings. True, but slightly oversimplified — the relationship is approximately linear within a range, not perfectly so across all strata.

Claim (Davidson): The REDUCE-IT trial's mineral oil placebo raised LDL by "9 to 10%" and increased inflammation, inflating EPA's apparent benefit. This is a contested interpretation. The mineral oil controversy is real and debated in peer-reviewed literature; Paul Ridker and others have raised this concern, and it is acknowledged by some independent analysts. However, the trial's principal investigators and others maintain that the benefit is genuine even accounting for the placebo issue. This is an unresolved scientific dispute, not an established fact either way.

Claim (Davidson): "Brain is 2% of dry weight [but] represents 50% of your body cholesterol." Davidson himself flagged uncertainty ("don't hold me to exact numbers"). Published estimates vary considerably; commonly cited figures are that the brain contains roughly 20–25% of total body cholesterol, not 50%. This specific figure is likely overstated, though the broader point — that the brain is exceptionally cholesterol-rich relative to its size — is correct.

**